ArticleCureus2025
GLP-1 Agonists and Cardiovascular Risk Markers in U.S. Adults: National Health and Nutrition Examination Survey (NHANES) 2011-2018.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimObesity and overweight remain major contributors to cardiovascular disease (CVD) in the United States. Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for glycemic control in type 2 diabetes, have demonstrated cardiometabolic benefits. However, limited population-based evidence exists on their association with cardiovascular risk markers among U.S. adults with overweight or obesity. This study aimed to evaluate the associations between GLP-1 receptor agonist use and cardiovascular risk markers (systolic and diastolic blood pressure, total cholesterol, high-density lipoprotein {HDL} cholesterol, and hemoglobin A1c) in a nationally representative sample of U.S. adults aged ≥18 years with overweight or obesity.
methodsData from the National Health and Nutrition Examination Survey (NHANES) 2011-2018 were analyzed using survey-weighted linear regression. Adults aged ≥18 years with overweight or obesity and complete biomarker data were included. Primary exposure was GLP-1 use; outcomes included systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and hemoglobin A1c.
resultsAmong 16,744 unweighted participants, GLP-1 users had significantly lower systolic blood pressure (β = -5.44, p<0.05) compared to non-users. No statistically significant differences were observed in lipid profiles or A1c after adjustment. Age, BMI, insurance status, and diabetes diagnosis were significant covariates.
conclusionGLP-1 receptor agonist use was associated with lower systolic blood pressure among adults with overweight or obesity. These findings highlight population-level associations that may inform future research on the cardiometabolic impact of GLP-1 therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.